A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

Conditions: Neoplasms (Cancer / Tumors); Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Breast Neoplasms; Pancreatic Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Glioma; Ovarian Neoplasms; Stomach Neoplasms
Sponsors: Harvard Medical School (HMS and HSDM)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 12, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments